Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: September 28, 2005
Last updated: October 2, 2015
Last verified: October 2015
This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.

Condition Intervention Phase
Breast Neoplasms
Drug: Gefitinib
Drug: Tamoxifen
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Strata 1: To compare the time to progression between 2 treatment arms (ZD1839/Nolvadex vs placebo/Nolvadex) [ Time Frame: Time to progression (progressive disease or death; equivalent to progression-free survival) ] [ Designated as safety issue: No ]
  • Strata 2: To compare the clinical benefit rate between 2 treatment arms (ZD1839/Nolvadex vs placebo/Nolvadex) [ Time Frame: Overall clinical benefit rate: Complete Response, Partial Response or Stable Disease > 24weeks after each combination ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To compare the clinical benefit rate between 2 treatment arms (ZD1839/Nolvadex vs placebo/Nolvadex) in Strata 1 and overall [ Time Frame: Overall clinical benefit rate: Complete Response, Partial Response or Stable Disease >24 weeks after each combination. Objective tumour resp defined according to RECIST criteria ] [ Designated as safety issue: No ]
  • To compare time to progression between 2 treatment arms (ZD1839/Nolvadex vs placebo/Nolvadex) in Strata 2 and overall [ Time Frame: Time to progression (progressive disease or death) ] [ Designated as safety issue: No ]
  • To compare the objective response rate between ZD1839/Nolvadex and placebo/Nolvadex in each strata and overall [ Time Frame: Objective tumour response (OR) defined according to RECIST criteria ] [ Designated as safety issue: No ]
  • To estimate duration of response for the ZD1839/Nolvadex and placebo/Nolvadex treatments in each strata and overall [ Time Frame: Duration of response (CR and PR) ] [ Designated as safety issue: No ]
  • To compare overall survival between the ZD1839/Nolvadex and placebo/Nolvadex in each strata [ Time Frame: Overall survival ] [ Designated as safety issue: No ]
  • To assess whether patients with high tumour levels of HER-2 and/or AIB1 demonstrate de novo resistance to Nolvadex therapy or have shorter TTP or response duration when compared with Nolvadex/ZD1839 treatment [ Time Frame: Time to progression (progressive disease or death), duration of response (CR and PR) ] [ Designated as safety issue: No ]
  • To compare the objective response rate between the ZD1839/Nolvadex and placebo/Nolvadex treatment arms in the subset of all patients with ER+ tumours staining 2+/3+ for Her2neu by IHC [ Time Frame: Objective tumour response (OR) defined according to RECIST criteria ] [ Designated as safety issue: No ]
  • To compare the safety and tolerability of ZD1839/Nolvadex to placebo/Nolvadex [ Time Frame: Safety (frequency and severity of adverse events) ] [ Designated as safety issue: Yes ]
  • To determine steady-state plasma trough concentrations of tamoxifen in all patients and to compare between the ZD1839/Nolvadex and placebo/Nolvadex treatment arms [ Time Frame: Tamoxifen (Cmin) steady-state plasma concentration ] [ Designated as safety issue: No ]
  • To determine steady-state plasma trough concentrations of ZD1839 and relate values to historical data [ Time Frame: ZD1839 (Cmin) steady-state plasma concentration ] [ Designated as safety issue: No ]
  • To relate steady-state plasma trough concentrations of ZD1839 to demographic, response, and safety variables [ Time Frame: ZD1839 (Cmin) steady-state plasma concentration ] [ Designated as safety issue: No ]
  • To assess the quality of life (QOL) and symptom relief based on the Functional Assessment of Cancer Therapy - Breast (FACT-B) on both treatment arms [ Time Frame: FACT-B questionnaire, FBSI (FACT-B Symptom Index) ] [ Designated as safety issue: No ]
  • To investigate subject hospital resource use and health status [ Time Frame: Hospitalisations and EQ-5D ] [ Designated as safety issue: No ]
  • Characterization of specific adverse events [ Time Frame: Characterization of adverse events such as alopecia, rash and diarrhea ] [ Designated as safety issue: Yes ]
  • To obtain tumour tissue for biologic studies in this patient population [ Time Frame: ER receptor, ErbB-1 &2 (immunohistochemistry) and other biological markers including Her2/neu, AIB1 ] [ Designated as safety issue: No ]

Enrollment: 317
Study Start Date: October 2003
Study Completion Date: June 2015
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
ZD1839 + Nolvadex
Drug: Gefitinib
Other Name: Iressa
Drug: Tamoxifen
Other Name: Nolvadex
Nolvadex + placebo
Drug: Tamoxifen
Other Name: Nolvadex


Ages Eligible for Study:   18 Years to 130 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed metastatic adenocarcinoma of the breast (seeTNM staging Appendix I) that is ER and/or PR positive as determined in local laboratories at each investigator site (central verification of ER status will be performed after the patient starts treatment
  • A tissue block from either the metastatic or primary tumor site is required.
  • WHO performance status (PS) 0-2
  • Patients must not be pregnant or breast-feeding. A negative pregnancy test is required within 7 days prior to randomization if pre- or peri-menopausal. Postmenopausal patients are defined as:
  • natural menopause with last menses > 1 year ago,
  • radiation induced oophorectomy with last menses > 1 year ago,
  • chemotherapy induced menopause with 1 year interval since last menses, or
  • serum FSH and LH and plasma estradiol levels in the postmenopausal range for the institution.
  • bilateral oophorectomy

Exclusion Criteria:

  • Patients cannot be on hormone replacement therapy or received prior chemotherapy for metastatic disease.
  • Patients previously treated with a Tyrosine Kinase inhibitor or have evidence of an active interstitial lung disease are not eligible.
  • Treatment with LH-RH analog.
  • Laboratory values as follow Bilirubin >1.5 times upper limit of normal ULN, alanine amino transferase (ALT) or aspartate amino transferase (AST) >2.5 times the ULN if no demonstrable liver metastases, or >5 times the ULN in the presence of liver metastases
  • Bone marrow function: WBC <1500 mm3
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00229697

  Hide Study Locations
United States, California
Research Site
Berkeley, California, United States
Research Site
Palm Springs, California, United States
United States, Missouri
Research Site
St. Louis, Missouri, United States
United States, New York
Research Site
New York, New York, United States
Research Site
Bahía Blanca, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
El Palomar, Argentina
Research Site
Resistencia, Argentina
Research Site
Rosario, Argentina
Research Site
San Miguel de Tucuman, Argentina
Research Site
Santa Fe, Argentina
Research Site
Vicente Lopez, Argentina
Research Site
Bentleigh East, Australia
Research Site
Newcastle, Australia
Research Site
Randwick, Australia
Research Site
Westmead, Australia
Research Site
Wodonga, Australia
Research Site
Brussels, Belgium
Research Site
Leuven, Belgium
Research Site
Wilrijk, Belgium
Research Site
Belo Horizonte, Brazil
Research Site
Curitiba, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Sao Paulo, Brazil
Research Site
São Paulo, Brazil
Canada, Alberta
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Canada, New Brunswick
Research Site
Saint John, New Brunswick, Canada
Canada, Ontario
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Canada, Quebec
Research Site
Montreal, Quebec, Canada
Research Site
Quebec, Canada
Research Site
Herlev, Denmark
Research Site
Lyon Cedex 08, France
Research Site
Mougins, France
Research Site
Poitiers, France
Research Site
Rouen, France
Research Site
Frankfurt, Germany
Research Site
Jena, Germany
Research Site
Kiel, Germany
Research Site
München, Germany
Research Site
Trier, Germany
South Africa
Research Site
Durban, South Africa
Research Site
Johannesburg, South Africa
Research Site
Klerksdorp, South Africa
Research Site
Observatory, South Africa
Research Site
Barcelona, Spain
Research Site
Córdoba, Spain
Research Site
Madrid, Spain
Research Site
Majadahonda, Spain
Research Site
Zaragoza, Spain
United Kingdom
Research Site
Colchester, United Kingdom
Research Site
Dundee, United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Nottingham, United Kingdom
Sponsors and Collaborators
Study Director: AstraZeneca Iressa Medical Science Director, MD AstraZeneca
  More Information

Additional Information:
Responsible Party: AstraZeneca Identifier: NCT00229697     History of Changes
Obsolete Identifiers: NCT00069290
Other Study ID Numbers: 1839IL/0225  D7917C00225 
Study First Received: September 28, 2005
Last Updated: October 2, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
Breast cancer
metastatic breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Bone Density Conservation Agents
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Selective Estrogen Receptor Modulators
Therapeutic Uses processed this record on May 03, 2016